Biotech targeting rare heart mutation with gene therapy scores $11M in Series A haul

Natalie Grover

Reporter

While cardiovascular disease is the leading cause of death globally — it is cancer that has benefited most from strides in precision medicine. Now that cardiovascular …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech targeting rare heart mutation with gene therapy scores $11M in Series A haul

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Biotech tar­get­ing rare heart mu­ta­tion with gene ther­a­py scores $11M in Se­ries A haul

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Biotech targeting rare heart mutation with gene therapy scores $11M in Series A haul